Steven B. Landau

2.0k total citations · 1 hit paper
19 papers, 1.6k citations indexed

About

Steven B. Landau is a scholar working on Immunology, Molecular Biology and Oncology. According to data from OpenAlex, Steven B. Landau has authored 19 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Immunology, 6 papers in Molecular Biology and 6 papers in Oncology. Recurrent topics in Steven B. Landau's work include Immune Cell Function and Interaction (5 papers), T-cell and B-cell Immunology (4 papers) and Lung Cancer Treatments and Mutations (4 papers). Steven B. Landau is often cited by papers focused on Immune Cell Function and Interaction (5 papers), T-cell and B-cell Immunology (4 papers) and Lung Cancer Treatments and Mutations (4 papers). Steven B. Landau collaborates with scholars based in United States, Canada and France. Steven B. Landau's co-authors include Steven P. Balk, Richard S. Blumberg, Pierre Paré, Gordon R. Greenberg, Gary Wild, Brian G. Feagan, Richard N. Fedorak, Albert Cohen, Margaret K. Vandervoort and John WD McDonald and has published in prestigious journals such as Science, New England Journal of Medicine and Proceedings of the National Academy of Sciences.

In The Last Decade

Steven B. Landau

19 papers receiving 1.6k citations

Hit Papers

Treatment of Ulcerative C... 2005 2026 2012 2019 2005 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Treatment of Ulcerative Colitis with a Humanized Antibody to the α 4 β 7 Integrin
    2005 535 citations Brian G. Feagan, Gordon R. Greenberg et al. New England Journal of Medicine profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Steven B. Landau 865 672 521 265 211 19 1.6k
Maria T. Abreu-Martin 375 0.4× 618 0.9× 439 0.8× 283 1.1× 367 1.7× 9 1.2k
Arnoud de Ru 571 0.7× 397 0.6× 490 0.9× 415 1.6× 322 1.5× 27 1.8k
Jeroen van Bergen 1.3k 1.5× 128 0.2× 437 0.8× 271 1.0× 253 1.2× 51 2.0k
Lisa M. Shackelton 283 0.3× 662 1.0× 486 0.9× 430 1.6× 456 2.2× 40 1.3k
Sharon B. Hoang 677 0.8× 363 0.5× 176 0.3× 320 1.2× 190 0.9× 9 1000
Donna Shows 676 0.8× 192 0.3× 240 0.5× 163 0.6× 498 2.4× 20 1.3k
Zhiqiong Yang 845 1.0× 516 0.8× 260 0.5× 222 0.8× 243 1.2× 13 1.3k
James A. Dromey 328 0.4× 256 0.4× 215 0.4× 229 0.9× 117 0.6× 14 887
Tim Bourne 748 0.9× 208 0.3× 178 0.3× 82 0.3× 274 1.3× 24 1.4k
Yvonne Kooy–Winkelaar 478 0.6× 129 0.2× 416 0.8× 227 0.9× 86 0.4× 27 1.2k

Countries citing papers authored by Steven B. Landau

Since Specialization
Citations

This map shows the geographic impact of Steven B. Landau's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Steven B. Landau with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Steven B. Landau more than expected).

Fields of papers citing papers by Steven B. Landau

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Steven B. Landau. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Steven B. Landau. The network helps show where Steven B. Landau may publish in the future.

Co-authorship network of co-authors of Steven B. Landau

This figure shows the co-authorship network connecting the top 25 collaborators of Steven B. Landau. A scholar is included among the top collaborators of Steven B. Landau based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Steven B. Landau. Steven B. Landau is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Ryan, David P., Janet E. Murphy, Devalingam Mahalingam, et al.. (2016). PD-016 Current results of a phase I study of DKN-01 in combination with paclitaxel (P) in patients (pts) with advanced DKK1+ esophageal cancer (EC) or gastro-esophageal junction tumors (GEJ). Annals of Oncology. 27. ii108–ii108. 6 indexed citations
2.
Ryan, David P., Janet E. Murphy, Devalingam Mahalingam, et al.. (2016). Current results of a phase I study of DKN-01, an anti-DKK1 antibody, in combination with paclitaxel (P) in patients (pts) with advanced DKK1+ esophageal cancer (EC) or gastro-esophageal junction tumors (GEJ).. Journal of Clinical Oncology. 34(15_suppl). e15525–e15525. 3 indexed citations
3.
Bendell, Johanna C., Janet E. Murphy, Devalingam Mahalingam, et al.. (2016). Phase I study of DKN-01, an anti-DKK1 antibody, in combination with paclitaxel (pac) in patients (pts) with DKK1+ relapsed or refractory esophageal cancer (EC) or gastro-esophageal junction tumors (GEJ).. Journal of Clinical Oncology. 34(4_suppl). 111–111. 15 indexed citations
4.
Eads, Jennifer R., Lipika Goyal, Stacey Stein, et al.. (2016). Phase I study of DKN-01, an anti-DKK1 antibody, in combination with gemcitabine (G) and cisplatin (C) in patients (pts) with advanced biliary cancer.. Journal of Clinical Oncology. 34(15_suppl). e15603–e15603. 8 indexed citations
5.
Shapiro, Geoffrey I., Afshin Dowlati, Patricia LoRusso, et al.. (2015). Abstract A49: Clinically efficacy of the BET bromodomain inhibitor TEN-010 in an open-label substudy with patients with documented NUT-midline carcinoma (NMC). Molecular Cancer Therapeutics. 14(12_Supplement_2). A49–A49. 37 indexed citations
6.
Edenfield, William J., Donald Richards, Svetislava J. Vukelja, et al.. (2014). A phase 1 study evaluating the safety and efficacy of DKN-01, an investigational monoclonal antibody (Mab) in patients (pts) with advanced non-small cell lung cancer.. Journal of Clinical Oncology. 32(15_suppl). 8068–8068. 15 indexed citations
7.
Kim, Youn H., Michael Krathen, Madeleine Duvic, et al.. (2014). A phase 1b study in cutaneous T-cell lymphoma (CTCL) with the novel topically applied skin-restricted histone deacteylase inhibitor (HDAC-i) SHP-141.. Journal of Clinical Oncology. 32(15_suppl). 8525–8525. 8 indexed citations
8.
Feagan, Brian G., Gordon R. Greenberg, Gary Wild, et al.. (2008). Treatment of Active Crohn's Disease With MLN0002, a Humanized Antibody to the α4β7 Integrin. Clinical Gastroenterology and Hepatology. 6(12). 1370–1377. 227 indexed citations
9.
10.
11.
Choung, Rok Seon, Dawn D. Ferguson, Joseph A. Murray, et al.. (2007). A novel partial 5HT3 agonist DDP733 after a standard refluxogenic meal reduces reflux events: a randomized, double‐blind, placebo‐controlled pharmacodynamic study. Alimentary Pharmacology & Therapeutics. 27(5). 404–411. 16 indexed citations
12.
Feagan, Brian G., Gordon R. Greenberg, Gary Wild, et al.. (2005). Treatment of Ulcerative Colitis with a Humanized Antibody to the α 4 β 7 Integrin. New England Journal of Medicine. 352(24). 2499–2507. 535 indexed citations breakdown →
13.
Feagan, Brian G., Gordon R. Greenberg, Gary Wild, et al.. (2000). An ascending dose trial of a humanized A4B7 antibody in ulcerative colitis (UC). Gastroenterology. 118(4). A874–A874. 76 indexed citations
14.
Landau, Steven B., et al.. (1995). Vγ (I) Expression in Human Intestinal Lymphocytes is Restricted. Immunological Investigations. 24(6). 947–955. 7 indexed citations
15.
Burke, Steven K., Steven B. Landau, Richard Green, et al.. (1994). Rat cluster of differentiation 1 molecule: Expression on the surface of intestinal epithelial cells and hepatocytes. Gastroenterology. 106(5). 1143–1149. 20 indexed citations
16.
Bhan, Atul K., et al.. (1993). Tissue distribution of the non-polymorphic major histocompatibility complex class I-like molecule, CD1d.. PubMed. 80(4). 561–5. 139 indexed citations
17.
Jarboe, Linda A., et al.. (1993). Glucose-dependent insulinotropic peptide: structure of the precursor and tissue-specific expression in rat.. Proceedings of the National Academy of Sciences. 90(5). 1992–1996. 57 indexed citations
18.
Blumberg, Richard S., Cox Terhorst, Paul A. Bleicher, et al.. (1991). Expression of a nonpolymorphic MHC class I-like molecule, CD1D, by human intestinal epithelial cells. The Journal of Immunology. 147(8). 2518–2524. 220 indexed citations
19.
Balk, Steven P., Ellen C. Ebert, Robin L. Blumenthal, et al.. (1991). Oligoclonal Expansion and CD1 Recognition by Human Intestinal Intraepithelial Lymphocytes. Science. 253(5026). 1411–1415. 206 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Maria T. Abreu-Martin Breakdown of academic impact, for papers by Arnoud de Ru Breakdown of academic impact, for papers by Jeroen van Bergen Breakdown of academic impact, for papers by Lisa M. Shackelton Breakdown of academic impact, for papers by Sharon B. Hoang Breakdown of academic impact, for papers by Donna Shows Breakdown of academic impact, for papers by Zhiqiong Yang Breakdown of academic impact, for papers by James A. Dromey Breakdown of academic impact, for papers by Tim Bourne Breakdown of academic impact, for papers by Yvonne Kooy–Winkelaar
Rankless by CCL
2026